In a study by Jia et al. (2017) on Chinese patients with advanced NSCLC who received cisplatin- or carboplatin-based chemotherapy, PFS was significantly shorter in patients with advanced NSCLC with KRAS G12V mutation than in patients with wild-type KRAS or other KRAS mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.